The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations
暂无分享,去创建一个
[1] M. Seto,et al. Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma , 1999, Journal of Gastroenterology.
[2] Junping Zhang,et al. MicroRNA-520b Inhibits Growth of Hepatoma Cells by Targeting MEKK2 and Cyclin D1 , 2012, PloS one.
[3] M. Romeih,et al. Wnt signaling in hepatocellular carcinoma: Analysis of mutation and expression of beta‐catenin, T‐cell factor‐4 and glycogen synthase kinase 3‐beta genes , 2003, Journal of gastroenterology and hepatology.
[4] C. J. Chen,et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.
[5] Y. I. Lee,et al. Hepatitis B virus-X protein upregulates the expression of p21wafl/cipl and prolongs G1→S transition via a p53-independent pathway in human hepatoma cells , 2000, Oncogene.
[6] J. LaBaer,et al. New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.
[7] R. Eils,et al. Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis , 2007, Hepatology.
[8] M. Roncalli,et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. , 1995, Gastroenterology.
[9] T. Sakurai,et al. Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1. , 2013, Biochemical and biophysical research communications.
[10] E. Yu,et al. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. , 2003, Cancer letters.
[11] G. Fattovich,et al. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.
[12] Amar Deep Sharma,et al. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. , 2008, Cancer cell.
[13] Yeup Yoon,et al. Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-κB-dependent expression of interleukin-8. , 2011, Cancer research.
[14] J Wade Harper,et al. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. , 2007, Molecular cell.
[15] Y. Choi,et al. Signaling through cyclin D-dependent kinases , 2014, Oncogene.
[16] J. Inazawa,et al. Activation of B‐Myb by E2F1 in hepatocellular carcinoma , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.
[17] W. Lau,et al. High frequency of p16INK4A gene alterations in hepatocellular carcinoma , 1999, Oncogene.
[18] Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. , 2006, Journal of hepatology.
[19] S. Osada,et al. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. , 2005, Journal of the American College of Surgeons.
[20] Rolf Gebhardt,et al. Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma , 2008, Molecular Cancer.
[21] James M. Roberts,et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. , 2003, Molecular cell.
[22] Ji-Yeon Kim,et al. Up-regulation of Cyclin D1 by HBx Is Mediated by NF-κB2/BCL3 Complex through κB Site of Cyclin D1 Promoter* , 2006, Journal of Biological Chemistry.
[23] J. Zucman‐Rossi,et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping , 2002, Oncogene.
[24] C. Sherr,et al. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase , 1994, Molecular and cellular biology.
[25] Christopher H. Contag,et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.
[26] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[27] H Nagahara,et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[28] L. Eriksson,et al. Induced drug resistance inhibits selection of initiated cells and cancer development. , 1997, Carcinogenesis.
[29] Chia-Hsin Chan,et al. Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression , 2010, TheScientificWorldJournal.
[30] M. Takamura,et al. Clinical significance of cell cycle inhibitors in hepatocellular carcinoma , 2013, Medical Molecular Morphology.
[31] Ji-Yeon Kim,et al. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. , 2006, The Journal of biological chemistry.
[32] M. Makuuchi,et al. p16INK4A Hypermethylation Is Associated with Hepatitis Virus Infection, Age, and Gender in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.
[33] S. Thorgeirsson,et al. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. , 2007, Gastroenterology.
[34] S. Fan,et al. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma , 2007, Cancer biology & therapy.
[35] M. Hayat. 1 Liver carcinoma , 2005 .
[36] J. Albrecht,et al. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver , 1998, Oncogene.
[37] Jing Fu,et al. Oncoprotein p28GANK binds to RelA and retains NF-κB in the cytoplasm through nuclear export , 2007, Cell Research.
[38] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[39] Hong-guang Zhu,et al. Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV‐associated hepatocarcinogenesis , 2007, Pathology international.
[40] Jean S. Campbell,et al. Liver regeneration. , 2012, Journal of hepatology.
[41] Hong-Yang Wang,et al. Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[42] C. Bréchot,et al. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma , 1990, Nature.
[43] S. Thorgeirsson,et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway , 2011, The Journal of experimental medicine.
[44] C. Maki,et al. Cdk2-dependent Inhibition of p21 Stability via a C-terminal Cyclin-binding Motif* , 2005, Journal of Biological Chemistry.
[45] K. Meyer,et al. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. , 1998, Gene.
[46] H. Hsu,et al. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. , 1998, Journal of hepatology.
[47] M. Chen,et al. Activation of p53 tumor suppressor by hepatitis C virus core protein. , 1999, Virology.
[48] Y. Shiratori,et al. Hepatitis C Virus Core Protein Enhances p53 Function through Augmentation of DNA Binding Affinity and Transcriptional Ability* , 2000, The Journal of Biological Chemistry.
[49] J. Zucman‐Rossi,et al. Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma , 2001, Oncogene.
[50] E. Wagner,et al. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.
[51] S. Seki,et al. Expression of the retinoblastoma gene product in human hepatocellular carcinoma. , 1995, Human pathology.
[52] S. Thorgeirsson,et al. Exploring genomic profiles of hepatocellular carcinoma , 2011, Molecular carcinogenesis.
[53] M. Ozturk,et al. Lithium‐mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells , 2005, International journal of cancer.
[54] H. Asakura,et al. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] Fangping Xu,et al. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. , 2006, American journal of clinical pathology.
[56] A. Wilkinson,et al. Gankyrin: a new oncoprotein and regulator of pRb and p53. , 2006, Trends in cell biology.
[57] M. Monden,et al. Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.
[58] H. Wang,et al. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1–Forkhead box M1 regulation loop , 2008, Hepatology.
[59] M. Barton,et al. Cascades of transcription regulation during liver regeneration. , 2011, The international journal of biochemistry & cell biology.
[60] T. Chibazakura,et al. Cyclin A overexpression induces chromosomal double-strand breaks in mammalian cells , 2009, Cell cycle.
[61] N. Hayashi,et al. Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.
[62] G. Michalopoulos. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. , 2010, The American journal of pathology.
[63] R. Assoian,et al. Transcriptional regulation of the cyclin D1 gene at a glance , 2008, Journal of Cell Science.
[64] I. Rusyn,et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[65] Hong-Yang Wang,et al. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling , 2011, Cell Research.
[66] M. Manns,et al. The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice , 2013, Hepatology.
[67] F. McCormick,et al. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.
[68] Lu-Yu Hwang,et al. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.
[69] K. McGlynn,et al. Epidemiology and natural history of hepatocellular carcinoma. , 2005, Best practice & research. Clinical gastroenterology.
[70] Jessica Zucman-Rossi,et al. Molecular classification of hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[71] G. Michalopoulos,et al. Beta-catenin is temporally regulated during normal liver development. , 2004, Gastroenterology.
[72] K. Engeland,et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma , 2000, International journal of cancer.
[73] M. Matsuda,et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis , 2003, International journal of cancer.
[74] D. Gilot,et al. Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth. , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[75] M. Mudryj,et al. Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle. , 2003, Virology.
[76] P. Kaldis,et al. Established and novel Cdk/cyclin complexes regulating the cell cycle and development. , 2011, Results and problems in cell differentiation.
[77] J. Isola,et al. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. , 2001, Cancer research.
[78] K. Nakayama,et al. Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. , 2013, Cancer cell.
[79] Wen Li,et al. Clinical significance of miR-221 and its inverse correlation with p27Kip1 in hepatocellular carcinoma , 2011, Molecular Biology Reports.
[80] H. Müller-Hermelink,et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. , 1997, Blood.
[81] Chun Cheng,et al. Mutant p27(Kip1) and its potential effect as hepatocellular gene therapy. , 2008, Archives of medical research.
[82] F. Bosman,et al. Germ‐line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma , 1997, Hepatology.
[83] J. Marrero,et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.
[84] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[85] Qifu Liu,et al. Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas. , 1998, World journal of gastroenterology.
[86] M. Loda,et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[87] P. Fisher,et al. Hepatitis B virus X protein increases expression of p21Cip‐1/WAF1/MDA6 and p27Kip‐1 in primary mouse hepatocytes, leading to reduced cell cycle progression , 2001 .
[88] K. Ogawa,et al. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis , 2006, Molecular carcinogenesis.
[89] Jian-Rong Yang,et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.
[90] K. Jang,et al. Cooperative repression of cyclin‐dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein , 2002, FEBS letters.
[91] H. Willenbring,et al. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice , 2008, Nature Protocols.
[92] S. M. Rubin. Deciphering the retinoblastoma protein phosphorylation code. , 2013, Trends in biochemical sciences.
[93] G. Hannon,et al. p21-containing cyclin kinases exist in both active and inactive states. , 1994, Genes & development.
[94] S. Imbeaud,et al. Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification , 2013, Hepatology.
[95] M. Makuuchi,et al. Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. , 2000, Cancer letters.
[96] S. Hirohashi,et al. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.
[97] O. Bachs,et al. Activation of Cdk4 and Cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin‐Cdk complexes , 1999, Hepatology.
[98] S. Thorgeirsson,et al. Comparative and integrative functional genomics of HCC , 2006, Oncogene.
[99] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[100] H. Kwun,et al. Transcriptional repression of p21(waf1) promoter by hepatitis B virus X protein via a p53-independent pathway. , 2001, Gene.
[101] J. Kao,et al. Prevention of hepatocellular carcinoma in the Asia–Pacific region: Consensus statements , 2010, Journal of gastroenterology and hepatology.
[102] I. Ng,et al. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. , 2001, Human pathology.
[103] Qi Chen,et al. Hepatitis B virus X protein promotes hypermethylation of p16(INK4A) promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis. , 2010, Experimental and molecular pathology.
[104] L. Gravitz. Liver cancer , 2014, Nature.
[105] Qi Chen,et al. Hepatitis B virus X protein induces hypermethylation of p16INK4A promoter via DNA methyltransferases in the early stage of HBV‐associated hepatocarcinogenesis , 2010, Journal of viral hepatitis.
[106] C-Y Chen,et al. Retinoblastoma protein modulates gankyrin–MDM2 in regulation of p53 stability and chemosensitivity in cancer cells , 2008, Oncogene.
[107] C. Guguen-Guillouzo,et al. Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1. , 1996, The Journal of biological chemistry.
[108] P. Gruppuso,et al. D-type cyclins and G1 progression during liver development in the rat. , 2005, Biochemical and biophysical research communications.
[109] Sheng-Nan Lu,et al. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[110] Tomoko Masuda,et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. , 2005, Cancer cell.
[111] C. Croce,et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.
[112] P. Schirmacher,et al. Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.
[113] C. Albanese,et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[114] K. Manova-Todorova,et al. Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.
[115] M. Joo,et al. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. , 2003, Journal of Korean medical science.
[116] W. Baek,et al. 5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. , 2000, Cancer letters.
[117] Robert L. Sutherland,et al. Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.
[118] E. Kipreos,et al. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. , 2012, Trends in cell biology.
[119] C. Verslype,et al. Molecular classification of hepatocellular carcinoma anno 2011. , 2011, European journal of cancer.
[120] N. Nishida,et al. Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma: A Systematic Review , 2011, Current genomics.
[121] M. Chung,et al. CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. , 2010, Anticancer research.
[122] I. Ng,et al. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. , 2004, Human pathology.
[123] S. Hirohashi,et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. , 1994, Cancer research.
[124] Arun J. Sanyal,et al. Zakim and Boyer's Hepatology: A Textbook of Liver Disease , 2016 .
[125] M. Makuuchi,et al. Over‐expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma , 1999, International journal of cancer.
[126] C. Guguen-Guillouzo,et al. Growth Factor Dependence of Progression through G and S Phases of Adult Rat Hepatocytes in Vitro , 1996, The Journal of Biological Chemistry.
[127] Maylis Delugin,et al. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients , 2007, Cell Division.
[128] E. Tabor. Hepatocellular carcinoma: global epidemiology. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[129] M. Roussel,et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.
[130] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[131] Xuegong Zhang,et al. An overview of hepatocellular carcinoma study by omics-based methods. , 2009, Acta biochimica et biophysica Sinica.
[132] Shiaw-Yih Lin,et al. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. , 2003, Cancer research.
[133] J. Albrecht,et al. Regulation of cyclin‐dependent kinase inhibitor p21WAF1/Cip1/Sdi1 gene expression in hepatic regeneration , 1997, Hepatology.
[134] K. Migita,et al. Liver architecture, cell function, and disease , 2009, Seminars in Immunopathology.
[135] Nathan H. Lents,et al. Cyclin A-CDK activity during G1 phase impairs MCM chromatin loading and inhibits DNA synthesis in mammalian cells , 2008, Cell cycle.
[136] M. Toyota,et al. Detection of hypermethylation of thep16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus , 2001, Gut.
[137] D. Calvisi,et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. , 2009, Gastroenterology.
[138] C. la Vecchia,et al. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. , 2009, Cancer letters.
[139] D. Stolz,et al. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. , 2001, Hepatology.
[140] Tae J. Lee,et al. A bistable Rb–E2F switch underlies the restriction point , 2008, Nature Cell Biology.
[141] C. Bréchot,et al. Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. , 1995, Journal of hepatology.
[142] James M. Roberts,et al. The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.
[143] C. Dai,et al. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine‐45 mutant β‐catenin , 2010, Hepatology.
[144] H. M. Reis,et al. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.
[145] Li-Huei Tsai,et al. Cyclin-dependent kinases: a family portrait , 2009, Nature Cell Biology.
[146] M. Ebara. [Hepatocellular carcinoma (HCC)]. , 1995, Ryōikibetsu shōkōgun shirīzu.
[147] Bruce Stillman,et al. Deregulation of cyclin E in human cells interferes with prereplication complex assembly , 2004, The Journal of cell biology.
[148] N. Nishida,et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.
[149] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[150] J. Diehl. Cycling to Cancer with Cyclin D1 , 2002, Cancer biology & therapy.
[151] A. Matsuura,et al. Loss of p27(Kip1) accelerates DNA replication after partial hepatectomy in mice. , 2003, The Journal of surgical research.
[152] Y. Dang,et al. Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro , 2013, BMC Cancer.
[153] Shih-Ming Huang,et al. Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells , 2013, PloS one.
[154] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[155] Martin Wasser,et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration , 2012, Proceedings of the National Academy of Sciences.
[156] P. Fortina,et al. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. , 2011, Gastroenterology.
[157] T. Okanoue,et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.
[158] M. Yano,et al. Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up‐regulation of cytoplasmic p21 expression , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[159] F. Izzo,et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy , 2012, Cell Death and Disease.
[160] M. Barbacid,et al. Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.
[161] K. Rao,et al. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine‐induced progressive liver carcinogenesis , 2007, Cell biology international.
[162] Xin Zheng,et al. Recombinant Human Adenovirus-p53 Injection Induced Apoptosis in Hepatocellular Carcinoma Cell Lines Mediated by p53-Fbxw7 Pathway, Which Controls c-Myc and Cyclin E , 2013, PloS one.
[163] M. Yuen,et al. Expression of c‐Myc, c‐Fos, and c‐Jun in hepatocellular carcinoma , 2001, Cancer.
[164] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[165] Liang Zhu,et al. Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation. , 2007, Carcinogenesis.
[166] Charles M. Perou,et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.
[167] Katsuhiko Itoh,et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas , 2000, Nature Medicine.
[168] J. Fassett,et al. Differential regulation of cyclins D1 and D3 in hepatocyte proliferation , 2002, Hepatology.
[169] F. Dick. Structure-function analysis of the retinoblastoma tumor suppressor protein – is the whole a sum of its parts? , 2007, Cell Division.
[170] Allan Balmain,et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene , 2004, Nature.
[171] J. Kononen,et al. Cyclin E overexpression and amplification in human tumours , 2003, The Journal of pathology.
[172] Zhou Zhu,et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma , 2013, Hepatology.
[173] G. Babcock,et al. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. , 2005, Cancer research.
[174] Xin Chen,et al. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. , 2009, Cancer research.
[175] Derek Y. Chiang,et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. , 2009, Journal of hepatology.
[176] James M. Roberts,et al. A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.
[177] Q. Zou,et al. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. , 2005, World journal of gastroenterology.
[178] A. Bahnassy,et al. The role of cyclins and cyclin dependent kinases in development and progression of hepatitis C virus-genotype 4-associated hepatitis and hepatocellular carcinoma. , 2011, Experimental and molecular pathology.
[179] G. Cao,et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3‐kinase/AKT/hypoxia‐inducible factor‐1α pathways , 2011, Hepatology.
[180] N. Tabibian. Hepatocellular carcinoma in the United States. , 1988, American family physician.
[181] I. Ng,et al. Expression of p27KIP1 and p21WAF1/CIP1 in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis , 2001 .
[182] Robert A. Weinberg,et al. Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.
[183] S. Reed,et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. , 2007, Cancer research.
[184] G. Farrell,et al. Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis , 2013, Journal of gastroenterology and hepatology.
[185] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[186] S. Thorgeirsson,et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.
[187] J. Jang,et al. Cyclin D1 overexpression in hepatocellular carcinoma. , 2001, Liver.
[188] E. Knudsen,et al. RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1 , 2009, Oncogene.
[189] T. Kodama,et al. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. , 2002, Biochemical and biophysical research communications.
[190] K. Nakayama,et al. Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.
[191] T. Hunter,et al. Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors , 2010, Cell cycle.
[192] H. Yang,et al. The repressive activity of hepatitis C virus core protein on the transcription of p21(waf1) is regulated by protein kinase A-mediated phosphorylation. , 2001, Virus research.
[193] Karl A. Merrick,et al. Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. , 2008, Molecular cell.
[194] J. Christensen,et al. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.
[195] M. Ozturk,et al. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells , 2001, Oncogene.
[196] J. Oh,et al. Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. , 2001, Cancer letters.
[197] C. Taylor. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas , 2006 .
[198] P. Dent,et al. Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. , 2001, Hepatology.
[199] W. Lingle,et al. Short Term Cyclin D1 Overexpression Induces Centrosome Amplification, Mitotic Spindle Abnormalities, and Aneuploidy* , 2005, Journal of Biological Chemistry.
[200] S. Hirohashi,et al. Reduced p27Kip1 expression in hepatocellular carcinomas. , 1998, Cancer letters.
[201] Y. N. Park,et al. Histopathological classification of hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[202] Y. Shyr,et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. , 2001, Cancer research.
[203] Y. Gong,et al. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E. , 2012, Gastroenterology.
[204] X. Graña,et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. , 2010, Gastroenterology.
[205] S. Rajalakshmi,et al. Development of resistance during the early stages of experimental liver carcinogenesis. , 1999, Carcinogenesis.
[206] J. Albrecht,et al. Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[207] W. Hahn,et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. , 2012, Blood.
[208] Chun Cheng,et al. Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro , 2011, Medical oncology.
[209] F. Ponchel,et al. P53 but not p16INK4a induces growth arrest in retinoblastoma-deficient hepatocellular carcinoma cells. , 2000, Journal of hepatology.
[210] T. Chibazakura. Cyclin Proteolysis and CDK Inhibitors: Two Redundant Pathways to Maintain Genome Stability in Mammalian Cells , 2004, Cell cycle.
[211] Yuqiong Liang,et al. Hepatitis C Virus Induces E6AP-Dependent Degradation of the Retinoblastoma Protein , 2007, PLoS pathogens.
[212] L. Hengst,et al. CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point , 2013, PLoS genetics.
[213] Yingying Wang,et al. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). , 2013, Human pathology.
[214] Y. Tan,et al. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. , 2001, World journal of gastroenterology.
[215] J. Yun,et al. MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells , 2009, Hepatology.
[216] Chien-Ru Liu,et al. Targeting c-Myc as a novel approach for hepatocellular carcinoma. , 2010, World journal of hepatology.
[217] B. Leggett,et al. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population , 1997, Hepatology.
[218] S. Hirohashi,et al. Reduced p21WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas , 1997, Hepatology.
[219] Nobuyuki Shishido,et al. Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.
[220] H. Vodermaier,et al. APC/C and SCF: Controlling Each Other and the Cell Cycle , 2004, Current Biology.
[221] H. El‐Serag,et al. Chapter 10 – Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis , 2012 .
[222] D. Stolz,et al. Changes in WNT/β‐catenin pathway during regulated growth in rat liver regeneration , 2001 .
[223] M. Kaneko,et al. Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors. , 1991, Japanese journal of clinical oncology.
[224] Lincoln D. Stein,et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.
[225] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[226] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[227] O. Bachs,et al. Differential association of p21Cip1 and p27Kip1 with cyclin E-CDK2 during rat liver regeneration. , 2000, Journal of hepatology.
[228] B. Clurman,et al. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation , 2008, Nature Reviews Cancer.
[229] Yuqiong Liang,et al. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[230] F. Dick,et al. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle , 2012, Cell Division.
[231] Miran Kim,et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.
[232] P. Tan,et al. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. , 2004, International journal of oncology.
[233] S. Boyault,et al. Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.
[234] F. Cerra,et al. Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver. , 1995, Biochemical and biophysical research communications.
[235] Xin Zheng,et al. Evaluation of Fbxw7 expression and its correlation with the expression of c‐Myc, cyclin E and p53 in human hepatocellular carcinoma , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.